Evidence map›Paper›PMID 30658316›Full record

ArticleTranslational oncology2019

Claudin 1 Is Highly Upregulated by PKC in MCF7 Human Breast Cancer Cells and Correlates Positively with PKCε in Patient Biopsies.

Anne A Blanchard, Xiuli Ma, Nan Wang, Sabine Hombach-Klonisch, Carla Penner, Arzu Ozturk, Thomas Klonisch, Marshall Pitz, Leigh Murphy, Etienne Leygue and 1 more

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Comparison of Fixation Methods for the Detection of Claudin 1 and E-Cadherin in Breast Cancer Cell Lines by Immunofluorescence.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Anne A BlanchardDepartment of Pathology, University of Manitoba; Department of Physiology and Pathophysiology, University of Manitoba. Electronic address: Anne.Blanchard@umanitoba.ca.
Xiuli MaDepartment of Pathology, University of Manitoba. Electronic address: Xiuli.ma@umanitoba.ca.
Nan WangDepartment of Pathology, University of Manitoba. Electronic address: nwang530@gmail.com.
Sabine Hombach-KlonischHuman Anatomy and Cell Science, University of Manitoba. Electronic address: Sabine.Hombach@umanitoba.ca.
Carla PennerDepartment of Pathology, University of Manitoba. Electronic address: crpenner@dsmanitoba.ca.
Arzu OzturkBiochemistry and Medical Genetics University of Manitoba. Electronic address: Arzu.Ozturk@umanitoba.ca.
Thomas KlonischHuman Anatomy and Cell Science, University of Manitoba. Electronic address: Thomas.Klonisch@umanitoba.ca.
Marshall PitzResearch Institute of Oncology and Hematology, Winnipeg, Manitoba, Canada. Electronic address: marshall.pitz@cancercare.mb.ca.
Leigh MurphyBiochemistry and Medical Genetics University of Manitoba; Research Institute of Oncology and Hematology, Winnipeg, Manitoba, Canada. Electronic address: Leigh.Murphy@umanitoba.ca.
Etienne LeygueHuman Anatomy and Cell Science, University of Manitoba; Biochemistry and Medical Genetics University of Manitoba. Electronic address: Etienne.Leygue@umanitoba.ca.
Yvonne MyalDepartment of Pathology, University of Manitoba; Department of Physiology and Pathophysiology, University of Manitoba; Research Institute of Oncology and Hematology, Winnipeg, Manitoba, Canada. Electronic address: Yvonne.myal@umanitoba.ca.
University of Manitoba · CAResearch Institute in Oncology and Hematology · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies provide compelling evidence to suggest that the tight junction protein claudin 1, aberrantly expressed in several cancer types, plays an important role in cancer progression. Dysregulation of claudin 1 has been shown to induce epithelial mesenchymal transition (EMT). Furthermore, activation of the ERK signaling pathway by protein kinase C (PKC) was shown to be necessary for EMT induction. Whether PKC is involved in regulating breast cancer progression has not been addressed. The PKC activator 12-O-tetradecanoylphorbol 13-acetate (TPA) was used to investigate the effect of PKC activity on claudin 1 transcription and protein levels, subcellular distribution, and alterations in EMT markers in human breast cancer (HBC) cell lines. As well, tissue microarray analysis (TMA) of a large cohort of invasive HBC biopsies was conducted to investigate correlations between claudin 1 and PKC isomers. TPA upregulated claudin 1 levels in all HBC cell lines analyzed. In particular, a high induction of claudin 1 protein was observed in the MCF7 cell line. TPA treatment also led to an accumulation of claudin 1 in the cytoplasm. Additionally, we demonstrated that the upregulation of claudin 1 was through the ERK signaling pathway. In patient biopsies, we identified a significant positive correlation between claudin 1, PKCα, and PKCε in ER+ tumors. A similar correlation between claudin 1 and PKCε was identified in ER- tumors, and high PKCε was associated with shorter disease-free survival. Collectively, these studies demonstrate that claudin 1 and the ERK signaling pathway are important players in HBC progression.

Identifiers

PMID30658316
PMCPMC6349319
OpenAlexW2909590780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.